NCT01864538View on ClinicalTrials.gov

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Metastatic Melanoma
Interventions
DRUG

TH-302

480 mg/m2 by iv infusion over 30 - 60 min on Days 1, 8, and 15 of a 28-day cycle.

Trial Locations (7)

10032

Columbia University Medical Center, New York

90025

The Angeles Clinic and Research Institute, Los Angeles

90404

UCLA, Los Angeles

T6G1Z2

Cross Cancer Institute, Edmonton

L8V5C2

Juravinski Cancer Centre, Hamilton

N6A4L6

London Health Sciences Centre, London

M5G2M9

Princess Margaret Hospital, Toronto

Sponsors

Lead Sponsor

ImmunoGenesis
All Listed Sponsors
lead

ImmunoGenesis

INDUSTRY

NCT01864538 - A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma | Biotech Hunter | Biotech Hunter